• 16 May 2019

LIBERUM: Genus* - PRRSv-resistance for China

Genus | GNS | 2,600 52 0.1% | Mkt Cap: 1,691m

    • Sophie Jourdier

    • 15 pages

Biotechnology image


 
Biotechnology image


Genus has announced a collaboration with Beijing Capital Agribusiness (BCA) to commercialise PRRSv-resistant pigs in China. BCA will bear full development and regulatory costs and will pay Genus $20m upon milestones.

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

LIBERUM: Genus* - CEO to step down in September

Companies: Genus

Genus PLC - Capital Markets day 2018

Companies: Genus

LIBERUM: Genus* - Beefing up the growth outlook

Companies: Genus

FTSE AIM success stories

Companies: ETOGNSBYGUTGASCNCCBOKDPZ

LIBERUM: Genus* - Solid 1H19 despite ASF disease headwinds

Companies: Genus

Copyright © 2019 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top